NCT00980707

CompletedPhase 4

Utility of Versican and Hyaluronan Measurement in Induced Sp...

Associated Scientists to Help Minimize Allergies Source

Associated Scientists to Help Minimize Allergies

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

AI-005 versican

Study Type

interventional

Actual enrollment (reported)

10

Locations

1 country

Sites

1

Timeline

Study Start

August 2009

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2010

Actual (reported)

Study Completion

November 2010

Actual (reported)

Brief Summary

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 10 participants
Study completion date: November 2010
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2009
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 17, 2009
Actual (reported)
First Posted
September 21, 2009
Actual (reported)
Primary Completion
June 2010
Actual (reported)
Study Completion
November 2010
Actual (reported)

Last Updated: January 19, 2012
Status Verified: January 2012
Last Update Submitted: January 18, 2012

Conditions

Allergic Asthma

Keywords

versicanhyaluronansputum

Outcome Measures

Primary Outcomes (1)

Compare hyaluronan and versican in asthmatics versus atopic non-asthmatics.
1 year

Study Arms (1)

inhaled corticosteroid

EXPERIMENTAL

All asthmatics will start inhaled corticosteroids.

Drug: Inhaled corticosteroid (fluticasone)

Interventions

Inhaled corticosteroid (fluticasone)Drug

inhaled fluticasone 220 ug/bid

Also known as: fluticasone

inhaled corticosteroid

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 45 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Allergic asthma defined as a positive methacholine challenge

You may not qualify if:

Sponsors & Collaborators

Associated Scientists to Help Minimize Allergies
Otherlead
Benaroya Research Institute
Othercollaborator
GlaxoSmithKline

Study Sites (1)

Associated Scientists to Help Minimize Allergies

Seattle, Washington, 98105, United States

MeSH Terms

Interventions

Fluticasone

Intervention Hierarchy (Ancestors)

AndrostadienesAndrostenesAndrostanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

Leonard C Altman, MD
Associated Scientists to Help Minimize Allergies
PRINCIPAL INVESTIGATOR

Enrollment

10 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 17, 2009

First Posted

September 21, 2009

Study Start

August 2009

Date type not reported

This date has not been verified as actual or estimated.

Phase 4

Completed

NCT00670930

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Phase 4Completed

NCT00492076

Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

Phase 4Completed

NCT00208234

Effect of Xolair on Airway Hyperresponsiveness

Phase 4Unknown

NCT00490425

Prevention of Asthma and Allergy by Probiotic Lactobacillus GG

Phase 4Completed

NCT04648813

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Phase 4Completed

NCT00813748

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing

Completed

Non-atopic patients

Contact the study team to confirm eligibility.

Industrycollaborator

Primary Completion

June 2010

Actual (reported)

Study Completion

November 2010

Actual (reported)

Last Updated

January 19, 2012

Record last verified: 2012-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00980707
Data provider: ClinicalTrials.gov
Source updated: 2012-01-19
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:25:12 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

inhaled corticosteroid

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations